{"id":"https://openalex.org/W2050400262","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0989","title":"GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab","display_name":"GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab","alternate_titles":[],"publication_year":2013,"publication_date":"2013-03-01","ids":{"openalex":"https://openalex.org/W2050400262","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0989","mag":"2050400262","pmid":"https://pubmed.ncbi.nlm.nih.gov/23209031"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-12-0989","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0989","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-0989","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2050400262"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112905292","display_name":"Christian A. Gerdes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Christian A. Gerdes","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077770252","display_name":"Valeria Nicolini","orcid":"https://orcid.org/0000-0003-4306-7849","observed_orcids":["https://orcid.org/0000-0003-4306-7849"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Valeria Gonzalez Nicolini","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006906885","display_name":"Sylvia Herter","orcid":"https://orcid.org/0000-0002-2446-696X","observed_orcids":["https://orcid.org/0000-0002-2446-696X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sylvia Herter","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025120043","display_name":"Erwin van Puijenbroek","orcid":"https://orcid.org/0009-0000-1349-3762","observed_orcids":["https://orcid.org/0009-0000-1349-3762"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Erwin van Puijenbroek","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sabine Lang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sabine Lang","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044903566","display_name":"Michaela Roemmele","orcid":"https://orcid.org/0000-0001-5247-0723","observed_orcids":["https://orcid.org/0000-0001-5247-0723"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michaela Roemmele","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066141340","display_name":"Ekkehard Moessner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ekkehard Moessner","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087526381","display_name":"Olivier Freytag","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Olivier Freytag","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112474280","display_name":"Thomas Friess","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas Friess","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031505278","display_name":"Carola Hermine Ries","orcid":"https://orcid.org/0000-0002-1855-8745","observed_orcids":["https://orcid.org/0000-0002-1855-8745"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Carola H. Ries","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018642317","display_name":"Birgit Bossenmaier","orcid":"https://orcid.org/0000-0002-3313-6161","observed_orcids":["https://orcid.org/0000-0002-3313-6161"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Birgit Bossenmaier","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102508028","display_name":"Hans Joachim Mueller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hans Joachim Mueller","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040318787","display_name":"Pablo Uma\u00f1a","orcid":"https://orcid.org/0000-0001-8206-2771","observed_orcids":["https://orcid.org/0000-0001-8206-2771"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Pablo Uma\u00f1a","raw_affiliation_strings":["Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Roche Glycart AG, pRED, Schlieren, Switzerland; and 2Roche Diagnostics GmbH, pRED, Penzberg, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5040318787","https://openalex.org/A5112905292"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":6.9005,"has_fulltext":false,"cited_by_count":133,"citation_normalized_percentile":{"value":0.97716063,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"19","issue":"5","first_page":"1126","last_page":"1138"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9448000192642212,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9448000192642212,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.04600000008940697,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-egfr-monoclonal-antibody","display_name":"anti-EGFR monoclonal antibody","score":0.9649999737739563},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.6259999871253967},{"id":"https://openalex.org/keywords/glycoengineering","display_name":"glycoengineering","score":0.7960000038146973},{"id":"https://openalex.org/keywords/fcgammariiia-binding","display_name":"Fc\u03b3RIIIa binding","score":0.8119999766349792},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9819999933242798},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9179999828338623},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.8930000066757202},{"id":"https://openalex.org/keywords/mouse-xenograft-model","display_name":"xenograft mouse model","score":0.7149999737739563}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8536111116409302},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.8067694902420044},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6546465754508972},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5621288418769836},{"id":"https://openalex.org/C2777092746","wikidata":"https://www.wikidata.org/wiki/Q5939625","display_name":"Humanized antibody","level":4,"score":0.476898193359375},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.39977848529815674},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3492411971092224},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34452229738235474},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.24197587370872498},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2061876356601715},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1611102819442749},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002478","descriptor_name":"Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006023","descriptor_name":"Glycoproteins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006031","descriptor_name":"Glycosylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000166","qualifier_name":"cytology","is_major_topic":false},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008822","descriptor_name":"Mice, Transgenic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011134","descriptor_name":"Polysaccharides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017452","descriptor_name":"Receptors, IgG","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060847","descriptor_name":"Metabolic Engineering","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-12-0989","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0989","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-0989","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:23209031","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23209031","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320318807","display_name":"Roche Innovation Center Zurich","ror":null}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":51,"referenced_works":["https://openalex.org/W628442368","https://openalex.org/W1523413020","https://openalex.org/W1581957323","https://openalex.org/W1930879408","https://openalex.org/W1965962344","https://openalex.org/W1967218337","https://openalex.org/W1979129905","https://openalex.org/W1985837387","https://openalex.org/W1989055139","https://openalex.org/W1997826619","https://openalex.org/W2016700351","https://openalex.org/W2027542837","https://openalex.org/W2038386885","https://openalex.org/W2043696829","https://openalex.org/W2048142144","https://openalex.org/W2051120695","https://openalex.org/W2052150715","https://openalex.org/W2057458801","https://openalex.org/W2063342567","https://openalex.org/W2064047613","https://openalex.org/W2075219903","https://openalex.org/W2077306776","https://openalex.org/W2079579628","https://openalex.org/W2081867678","https://openalex.org/W2091057822","https://openalex.org/W2095201384","https://openalex.org/W2096617104","https://openalex.org/W2097121246","https://openalex.org/W2106789440","https://openalex.org/W2110990893","https://openalex.org/W2115175735","https://openalex.org/W2122080125","https://openalex.org/W2122618533","https://openalex.org/W2124910438","https://openalex.org/W2128402413","https://openalex.org/W2130930654","https://openalex.org/W2134142320","https://openalex.org/W2134519717","https://openalex.org/W2136509556","https://openalex.org/W2141167338","https://openalex.org/W2145627626","https://openalex.org/W2151557562","https://openalex.org/W2152155460","https://openalex.org/W2156700619","https://openalex.org/W2160798258","https://openalex.org/W2164837623","https://openalex.org/W2168479321","https://openalex.org/W2168841302","https://openalex.org/W2171756567","https://openalex.org/W2182452189","https://openalex.org/W6631163079"],"related_works":["https://openalex.org/W2171528830","https://openalex.org/W2307025461","https://openalex.org/W2063342567","https://openalex.org/W2589972844","https://openalex.org/W1971407651","https://openalex.org/W2160836836","https://openalex.org/W2183107537","https://openalex.org/W2536527912","https://openalex.org/W2145627626","https://openalex.org/W2314994356"],"abstract_inverted_index":{"PURPOSE:":[0],"Anti-EGF":[1],"receptor":[2],"(EGFR)":[3],"antibodies":[4],"and":[5,57,76,144,162,181,233],"small-molecule":[6],"tyrosine":[7],"kinase":[8],"inhibitors":[9],"have":[10],"shown":[11],"activity":[12],"in":[13,36,169,192,195,210,227],"epithelial":[14],"tumors;":[15],"however,":[16],"agents":[17],"that":[18,219],"work":[19],"by":[20,64,104],"blocking":[21],"the":[22,29,43,58,65,68,72,88,107,160],"EGFR":[23,135],"growth":[24],"signal":[25],"are":[26],"ineffective":[27],"when":[28,208],"oncogenic":[30],"stimulus":[31],"arises":[32],"downstream,":[33],"such":[34],"as":[35,151],"tumors":[37,232],"with":[38,97,176,212,229,242],"KRAS":[39],"mutations.":[40],"Antibodies":[41],"of":[42,60,67,71,90,106,114,132,165,173,198,203,240],"IgG1":[44],"subclass":[45],"can":[46],"also":[47,235],"kill":[48],"tumor":[49,183],"cells":[50,184],"directly":[51],"through":[52],"antibody-dependent":[53],"cell-mediated":[54],"cytotoxicity":[55],"(ADCC),":[56],"efficacy":[59,194],"this":[61],"is":[62],"determined":[63],"interaction":[66],"Fc":[69,77,112],"portion":[70],"target":[73],"cell-bound":[74],"antibody":[75,96],"receptors":[78],"present":[79],"on":[80],"immune":[81],"effector":[82],"cells.":[83],"EXPERIMENTAL":[84],"DESIGN:":[85],"We":[86],"report":[87],"development":[89],"GA201,":[91],"a":[92,148,196,237],"novel":[93],"anti-EGFR":[94],"monoclonal":[95],"enhanced":[98,124,171,187],"ADCC":[99,174,188],"properties.":[100],"GA201":[101,115,133,154,204,220],"was":[102,116,205],"derived":[103],"humanization":[105],"rat":[108],"ICR62":[109],"antibody.":[110],"The":[111],"region":[113],"glycoengineered":[117],"to":[118,126,134,147,158],"contain":[119],"bisected,":[120],"afucosylated":[121],"carbohydrates":[122],"for":[123],"binding":[125,131,157],"Fc\u03b3RIIIA.":[127,166],"RESULTS:":[128],"In":[129],"vitro":[130],"inhibited":[136],"EGF":[137],"ligand":[138],"binding,":[139],"EGFR/HER2":[140],"heterodimerization,":[141],"downstream":[142],"signaling,":[143],"cell":[145],"proliferation":[146],"similar":[149],"extent":[150],"cetuximab.":[152],"However,":[153],"exhibited":[155],"superior":[156,191],"both":[159,179],"low-":[161],"high-affinity":[163],"variants":[164],"This":[167,186],"resulted":[168],"significantly":[170],"induction":[172],"compared":[175],"cetuximab":[177,226],"against":[178],"KRAS-wild-type":[180],"-mutant":[182],"lines.":[185],"translated":[189],"into":[190],"vivo":[193],"series":[197],"mouse":[199],"xenograft":[200],"models.":[201],"Efficacy":[202],"further":[206],"increased":[207],"administered":[209],"combination":[211],"chemotherapy":[213],"(irinotecan).":[214],"CONCLUSIONS:":[215],"These":[216],"data":[217],"suggest":[218],"may":[221,234],"be":[222],"more":[223],"effective":[224],"than":[225],"patients":[228,241],"EGFR-positive":[230],"solid":[231],"represent":[236],"first-in-class":[238],"treatment":[239],"KRAS-mutated":[243],"tumors.":[244],"Clin":[245],"Cancer":[246],"Res;":[247],"19(5);":[248],"1126-38.":[249],"\u00a92012":[250],"AACR.":[251]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2050400262","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":24},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
